

TABLE 1—NOTICES OF UPDATES TO RECOGNIZED OR UPDATED SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA (STIC) BY DRUG ¹—Continued

Drug	Route of administration	Action taken	Therapeutic category	Date
Piperacillin and Tazobactam.	Injection	FDA has updated STIC (MIC and disk diffusion) for Enterobacterales. FDA has recognized M100 standard for susceptible and resistant breakpoints and updated an intermediate breakpoint. FDA does not recognize M100 standard for a susceptible dose dependent breakpoint. (Rationale available at https://www.fda.gov/drugs/development-resources/fda-rationale-piperacillin-tazobactam-breakpoints-enterobacterales).	Antibacterial	1/17/2023
Plazomicin	Injection	FDA recognizes M100 standard (MIC and disk diffusion) for Enterobacterales.	Antibacterial	4/21/2023
Polymyxin B	Injection	FDA does not recognize M100 standard (MIC) for Enterobacterales, <i>Pseudomonas aeruginosa</i> , or <i>Acinetobacter</i> spp. (Rationale available at https://www.fda.gov/drugs/development-resources/fda-rationale-polymyxin-breakpoints-enterobacterales-pseudomonas-aeruginosa-and-acinetobacter-spp).	Antibacterial	1/17/2023
Rezafungin	Injection	FDA identified STIC (MIC and disk diffusion) for <i>C. albicans</i> , <i>C. glabrata</i> , and <i>C. tropicalis</i> . FDA has reviewed STIC (MIC) for <i>C. parapsilosis</i> , and the M27M44S standard is recognized. FDA identified STIC (disk diffusion) for <i>C. parapsilosis</i> .	Antifungal	4/18/2023
Sulbactam and Durlibactam.	Injection	FDA identified STIC (MIC and disk diffusion) for <i>Acinetobacter baumannii-calcoaceticus</i> complex.	Antibacterial	5/25/2023
Tobramycin	Injection	FDA does not recognize M100 standard (MIC and disk diffusion) for Enterobacterales and <i>Pseudomonas aeruginosa</i> .	Antibacterial	4/21/2023

¹ M100 standard in the table refers to Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 33rd ed. CLSI supplement M100; 2023.

Dated: April 4, 2024.
Lauren K. Roth,
 Associate Commissioner for Policy.
 [FR Doc. 2024-07495 Filed 4-8-24; 8:45 am]
BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Hispanic Community Health Study—Study of Latinos (HCHS-SOL) Coordinating Center.
Date: April 30, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Susan Wohler Sunnarborg, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA National, Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7987, susan.sunnarborg@nih.gov.
 (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: April 4, 2024.
Melanie J. Pantoja,
 Program Analyst, Office of Federal Advisory Committee Policy.
 [FR Doc. 2024-07499 Filed 4-8-24; 8:45 am]
BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council on Alcohol Abuse and Alcoholism.

This will be a hybrid meeting held in-person and virtually and will be open to the public as indicated below. Individuals who plan to attend in-person or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting